Enhabit (EHAB) Stock Price, News & Analysis

Company Overview

Enhabit, Inc. (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.

The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services. Enhabit’s clinical teams work closely with primary care physicians, hospitals and other care providers to execute tailored care plans, monitor patient progress and adjust treatments as needed. Leveraging proprietary care-management technology, Enhabit aims to streamline clinical workflows, improve care coordination and reduce avoidable hospital readmissions.

Enhabit operates across more than 20 states in both urban and rural markets, having expanded its footprint through a combination of organic growth and strategic acquisitions of regional home health and hospice providers. The company’s leadership team comprises seasoned healthcare executives with decades of experience in home health, hospice and care management. With an emphasis on quality, compliance and patient satisfaction, Enhabit continues to pursue opportunities that strengthen its service capabilities and extend its reach to communities nationwide.

Key Stats

• Today's Range: $7.85 to $8.14
• 50-Day Range: $6.53 to $8.17
• 52-Week Range: $6.47 to $10.90
• Volume: 442,204 shs
• Average Volume: 391,692 shs
• Market Capitalization: $400.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Hold

Enhabit Stock Analysis - MarketRank™

Enhabit scored higher than 63% of companies evaluated by MarketBeat, and ranked 436th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Enhabit has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Enhabit is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Enhabit has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 31.82%

Earnings Growth

Earnings for Enhabit are expected to grow by 31.82% in the coming year, from $0.22 to $0.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enhabit is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enhabit is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enhabit has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.76% of the float of Enhabit has been sold short.

Short Interest Ratio / Days to Cover

Enhabit has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enhabit has recently decreased by 7.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enhabit does not currently pay a dividend.

Dividend Growth

Enhabit does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.76% of the float of Enhabit has been sold short.

Short Interest Ratio / Days to Cover

Enhabit has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enhabit has recently decreased by 7.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.75

News Sentiment

Enhabit has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Enhabit this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Enhabit to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Enhabit insiders have bought more of their company's stock than they have sold. Specifically, they have bought $76,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Enhabit is held by insiders.

EHAB Stock Analysis - Frequently Asked Questions

How have EHAB shares performed this year?

Enhabit's stock was trading at $7.81 on January 1st, 2025. Since then, EHAB stock has increased by 1.3% and is now trading at $7.91.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) announced its quarterly earnings results on Wednesday, August, 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.03. The firm had revenue of $266.10 million for the quarter, compared to the consensus estimate of $263.39 million. Enhabit had a positive trailing twelve-month return on equity of 2.72% and a negative net margin of 12.84%.
Read the conference call transcript.

Who are Enhabit's major shareholders?

Enhabit's top institutional investors include 8 Knots Management LLC (7.60%), AREX Capital Management LP (4.90%), Systematic Financial Management LP (3.83%) and Paradice Investment Management LLC (3.43%). Insiders that own company stock include Ryan Solomon, Jeffrey Bolton, Stuart M Mcguigan, Ronald Leroy Langham Jr, L Edward Shaw Jr, Erin Hoeflinger, Gregory S Rush and Collin Mcquiddy.
View institutional ownership trends.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enhabit own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enhabit investors own include Alphabet (GOOG), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX), Home Depot (HD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NYSE:EHAB
• CIK: 1803737
• Web: www.ehab.com
• Phone: 214-239-6500
• Fax: N/A
• Employees: 10,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enhabit: $8.67
• High Price Target: $9.50
• Low Price Target: $8.00
• Potential Upside/Downside: +9.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 35.95
• P/E Growth: N/A
• Net Income: -$156.20 million
• Net Margins: -12.84%
• Pretax Margin: -12.17%
• Return on Equity: 2.72%
• Return on Assets: 1.25%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $1.03 billion
• Price / Sales: 0.39
• Cash Flow: $3.99 per share
• Price / Cash Flow: 1.98
• Book Value: $10.92 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 50,690,000
• Free Float: 48,967,000
• Market Cap: $400.96 million
• Optionable: Optionable
• Beta: 1.69